Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 6.80 +0.08 (+1.19%)
As of 07/13/2026 11:53 AM Eastern
Compare

AGY vs. HCM, AMYT, APH, ANCR, and BXP

Should you buy Allergy Therapeutics stock or one of its competitors? MarketBeat compares Allergy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allergy Therapeutics include HUTCHMED (HCM), Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), and Beximco Pharmaceuticals (BXP). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Allergy Therapeutics compare to HUTCHMED?

Allergy Therapeutics (LON:AGY) and HUTCHMED (LON:HCM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Allergy Therapeutics has higher earnings, but lower revenue than HUTCHMED. Allergy Therapeutics is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M7.52-£52.59M-£0.97N/A
HUTCHMED£548.51M2.69-£52.98M£53.003.24

In the previous week, HUTCHMED had 2 more articles in the media than Allergy Therapeutics. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Allergy Therapeutics. Allergy Therapeutics' average media sentiment score of 0.00 beat HUTCHMED's score of -0.40 indicating that Allergy Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Allergy Therapeutics Neutral
HUTCHMED Neutral

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Allergy Therapeutics has a beta of 0.872, meaning that its share price is 13% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market.

HUTCHMED has a net margin of 163.84% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
HUTCHMED 163.84%36.88%-5.90%

Summary

HUTCHMED beats Allergy Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to Amryt Pharma?

Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Amryt PharmaN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£210.24M0.00N/A-£33.00N/A
Allergy Therapeutics£57.29M7.52-£52.59M-£0.97N/A

In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Amryt Pharma Neutral
Allergy Therapeutics Neutral

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Amryt Pharma and Allergy Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Allergy Therapeutics (LON:AGY) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Comparatively, 12.0% of Alliance Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Alliance Pharma -6.00%-5.04%5.98%

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M7.52-£52.59M-£0.97N/A
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A

Allergy Therapeutics has a beta of 0.872, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Alliance Pharma Neutral

Summary

Alliance Pharma beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Animalcare Group?

Animalcare Group (LON:ANCR) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Animalcare Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Animalcare Group£89.11M2.59£36.55M£7.3045.75
Allergy Therapeutics£57.29M7.52-£52.59M-£0.97N/A

Animalcare Group has a net margin of 5.70% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Animalcare Group5.70% 4.46% 2.97%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Animalcare Group had 1 more articles in the media than Allergy Therapeutics. MarketBeat recorded 1 mentions for Animalcare Group and 0 mentions for Allergy Therapeutics. Animalcare Group's average media sentiment score of 0.67 beat Allergy Therapeutics' score of 0.00 indicating that Animalcare Group is being referred to more favorably in the media.

Company Overall Sentiment
Animalcare Group Positive
Allergy Therapeutics Neutral

Animalcare Group has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.872, meaning that its share price is 13% less volatile than the broader market.

14.3% of Animalcare Group shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 30.1% of Animalcare Group shares are owned by company insiders. Comparatively, 3.6% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Animalcare Group beats Allergy Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to Beximco Pharmaceuticals?

Beximco Pharmaceuticals (LON:BXP) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Beximco Pharmaceuticals has a net margin of 16.57% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.57% 7.76% 6.97%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Allergy Therapeutics Neutral

Beximco Pharmaceuticals has a beta of 0.251, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.872, suggesting that its stock price is 13% less volatile than the broader market.

Beximco Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Allergy Therapeutics£57.29M7.52-£52.59M-£0.97N/A

Summary

Beximco Pharmaceuticals beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£430.61M£6.39B£7.05B£2.85B
Dividend Yield8.33%2.82%2.68%6.17%
P/E Ratio-7.015.0327.15368.18
Price / Sales7.521,659.36587.9284,612.72
Price / Cash3.6610.1829.2227.87
Price / Book68.9110.9010.757.49
Net Income-£52.59M£20.27B£3.58B£5.89B
7 Day Performance6.50%-0.94%-2.07%-0.19%
1 Month Performance-14.68%-1.21%3.31%-1.00%
1 Year Performance-15.00%9.06%26.35%61.67%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 6.80
+1.2%		N/A-17.6%£430.61M£57.29MN/A612
HCM
HUTCHMED
N/AGBX 170.65
-6.2%		N/A-27.3%£1.47B£548.51M3.221,760
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290
APH
Alliance Pharma
N/AGBX 64.70
flat		N/AN/A£350.32M£183.50MN/A91,000
ANCR
Animalcare Group
N/AGBX 333
-0.1%		N/A+14.4%£229.92M£89.11M45.62220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel